Skip to main content

Advertisement

SpringerLink
Log in

The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

OncotypeDX® (ODX) is a well-validated assay for breast cancer treatment planning. We explored whether the conventional pathological factors could pick up high risk patients without the help of the ODX.

Methods

The ODX was performed on 139 hormone receptor-positive invasive breast cancers in a single Japanese institution. The recurrence risk was compared between the ODX and the St. Gallen Consensuses. The correlations were analyzed between the Recurrence Score (RS) measured by ODX and the pathological factors. In addition, we performed a follow-up survey and examined the association of the RS with the confirmed recurrence or death.

Results

The ODX classified 68 (49 %) as low RS, 52 (37 %) as intermediate RS, and 19 (14 %) as high RS cases. Correlations were noted between RS and progesterone receptor (PR) (r = −0.53), Ki-67 (r = 0.42), and nuclear grade (NG) (r = 0.41). None had a high RS with PR(3+) or NG1. Only one high RS patient had a Ki-67 (<20 %). The combinations of high RS with PR(0)/Ki-67 (≥20 %) and PR(1+)/Ki-67 (≥20 %) were 70 and 58 %, respectively. The combinations with high RS and PR(0)/NG3, PR(0)/NG2, and PR(1+)/NG3 were 83, 75, and 75 %, respectively. The median follow-up was 39.1 months (range 24.0–67.8). There were one low RS (1 %), four intermediate RS (8 %), and three high RS patients (16 %) who developed local or distant recurrence.

Conclusion

Hormone receptor-positive invasive breast cancers are stratified with the combinations of PR/Ki-67 or PR/NG. Some of the high recurrence risk cases might be identified without the ODX.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  CAS  PubMed  Google Scholar 

  2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  CAS  PubMed  Google Scholar 

  3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.

    Article  CAS  PubMed  Google Scholar 

  6. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

    Article  CAS  PubMed  Google Scholar 

  7. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol. 2009;20:1319–29.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology™. Breast Cancer. 2011; NCCN® Practice Guidelines in Oncology. Version 2.

  9. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.

    Article  CAS  PubMed  Google Scholar 

  10. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.

    Article  CAS  PubMed  Google Scholar 

  11. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.

    Google Scholar 

  13. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health Recurrence Score in early breast cancer. J Clin Oncol. 2011;29:4273–8.

    Article  PubMed  Google Scholar 

  15. Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, et al. Prediction of the Oncotype DX Recurrence Score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol. 2012;26:658–64.

    Article  Google Scholar 

  16. Ingoldsby H, Webber M, Wall D, Scarrott C, Newell J, Callagy G. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. Breast. 2013;22:879–86.

    Google Scholar 

  17. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. 2013;24:661–8.

    Article  CAS  PubMed  Google Scholar 

  18. Kurebayashi J, Kanomata N, Shimo T, Yamashita T, Aogi K, Nishimura R. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone. Breast Cancer. 2012. doi:10.1007/s12282-012-0380-z.

  19. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31:203–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–35.

    Article  CAS  PubMed  Google Scholar 

  21. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Breast Surgical Oncology, St. Luke’s International Hospital, Tokyo, Japan

    Toshinao Onoda, Hideko Yamauchi, Hiroshi Yagata, Naoki Hayashi & Atsushi Yoshida

  2. Breast Center, Showa University, Tokyo, Japan

    Toshinao Onoda & Seigo Nakamura

  3. Breast Surgery, Yokohama Asahi Central General Hospital, Yokohama, Japan

    Toshinao Onoda & Osamu Sakurai

  4. Breast and Endocrine Surgery, St. Marianna School of Medicine, Kawasaki, Japan

    Koichiro Tsugawa

  5. Pathological Diagnosis, St. Luke’s International Hospital, Tokyo, Japan

    Koyu Suzuki

Authors
  1. Toshinao Onoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideko Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Yagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichiro Tsugawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsushi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Koyu Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Osamu Sakurai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seigo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshinao Onoda.

About this article

Cite this article

Onoda, T., Yamauchi, H., Yagata, H. et al. The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients. Breast Cancer 22, 406–412 (2015). https://doi.org/10.1007/s12282-013-0495-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-013-0495-x

Keywords

Search

Navigation